CINJ 020702: A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone and Choline Magnesium Trisalicylate in the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tetradecanoylphorbol acetate (Primary) ; Choline magnesium trisalicylate; Dexamethasone
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

12 Jun 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
06 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight